Par Pharmaceuticals To Restate Financials

Par Pharmaceuticals Cos. Inc. (PRX) must restate financial results for 2004, 2005 and the first quarter of 2006 due to accounting errors. Reported revenue is expected to drop by as much as $55 million. The stock price plunged $4.78 to close at $13.47.